A role for the N-acetyltransferase 2 (NAT2) genetic polymorphism in cancer risk has been the subject of numerous studies. Although comprehensive reviews of the NAT2 acetylation polymorphism have been published elsewhere, the objective of this paper is to briefly highlight some important features of the NAT2 acetylation polymorphism that are not universally accepted to better understand the role of NAT2 polymorphism in carcinogenic risk assessment. NAT2 slow acetylator phenotype(s) infer a consistent and robust increase in urinary bladder cancer risk following exposures to aromatic amine carcinogens. However, identification of specific carcinogens is important as the effect of NAT2 polymorphism on urinary bladder cancer differs dramatically between monoarylamines and diarylamines. Misclassifications of carcinogen exposure and NAT2 genotype/phenotype confound evidence for a real biological effect. Functional understanding of the effects of NAT2 genetic polymorphisms on metabolism and genotoxicity, tissue-specific expression and the elucidation of the molecular mechanisms responsible are critical for the interpretation of previous and future human molecular epidemiology investigations into the role of NAT2 polymorphism on cancer risk. Although associations have been reported for various cancers, this paper focuses on urinary bladder cancer, a cancer in which a role for NAT2 polymorphism was first proposed and for which evidence is accumulating that the effect is biologically significant with important public health implications.
Introduction
The N-acetyltransferase 2 (NAT2) acetylation polymorphism was discovered over 50 years ago when individual variability in isoniazid neurotoxicity was attributed to genetic variability in N-acetylation (Hughes et al., 1954) . The importance increased when it was discovered that many aromatic amine and hydrazine drugs are subject to the acetylation polymorphism, thus affecting therapeutic efficacy and toxicity . It was soon apparent that many environmental and occupational aromatic amine carcinogens undergo catalysis by N-acetyltransferases (Hein, 1988) . Thus, a role for NAT2 acetylation polymorphism in individual risk to various cancers in which aromatic amines play an etiologic role is biologically plausible and has been the subject of numerous studies.
N-acetyltransferase isozymes NAT1 and NAT2
Whereas the N-acetylation of isoniazid and sulfamethazine divided human populations by NAT2 acetylator phenotypes, the N-acetylation of drugs such as paminosalicylic acid yielded apparently unimodal distribution of individuals (Jenne, 1965) . The biochemical basis relates to substrate specificity and molecular genetics of two distinct N-acetyltransferase isozymes, subsequently identified as N-acetyltransferase 1 (NAT1) and NAT2 (Vatsis et al., 1995) . The crystallographic structures of several prokaryotic N-acetyltransferases have been published (Sinclair et al., 2000; Sandy et al., 2002; Dupret and Rodrigues-Lima, 2005) . Although crystal structures of mammalian NAT1 and NAT2 have yet to be reported, molecular modeling of both human NAT1 (Rodrigues-Lima et al., 2001 ) and NAT2 (Rodrigues-Lima and Dupret, 2002) ). The Cys 68 residue is critical for transferring the acetyl moiety from acetyl coenzyme A cofactor to acceptor substrates (Dupret and Grant, 1992) . Aromatic amines and hydrazines (N-acetylation), N-hydroxyaromatic and -heterocyclic amines (O-acetylation) and N-hydroxy-N-acetyl-aromatic amines (N, O-acetylation) are examples of acceptor substrates for both NAT1 and NAT2 (Hein, 1988) . Although both human NAT1 and NAT2 catalyse these reactions, human NAT2 has a three-to four-fold higher affinity than NAT1 for urinary bladder carcinogens such as 4-aminobiphenyl (ABP) and b-naphthylamine (BNA) (Hein et al., 1993b) . This finding is consistent with the hypothesis that the effect of NAT2 polymorphism on urinary bladder cancer is more prevalent at low-dose aromatic amine exposures (Vineis et al, 1994 (Vineis et al, , 2004 .
Animal models
NAT1 and NAT2 in animal models such as rabbit, mouse, Syrian hamster and rat are highly homologous to both human NAT1 and NAT2 (Hein et al., 1997; Hein, 2002) . Substrate specificities for Syrian hamster, mouse and rat NAT2 may resemble human NAT1 more than they do human NAT2 . Several different mechanisms are responsible for NAT2 polymorphisms in non-human species. The molecular basis for slow acetylator phenotype is NAT2 gene deletion in the rabbit (Blum et al., 1989) , a nonsense single-nucleotide polymorphism (SNP) yielding a truncated NAT2 enzyme in the Syrian hamster (Ferguson et al., 1994 (Ferguson et al., , 1996 Nagata et al., 1994) , and missense SNP(s) in the mouse and rat . Both NAT1 and NAT2 have been identified and partially purified from Syrian hamster liver Smith and Hanna, 1986; Trinidad et al., 1989; Ozawa et al., 1990) , intestine (Smith and Hanna, 1986) , colon (Hein et al., 1993a) , prostate and urinary bladder cytosols. Expression of NAT1 and NAT2 isozymes also has been reported in rapid and slow acetylator mouse and rat (Hein et al., 1991a) liver cytosols.
Phenotypic expression of the NAT2 polymorphism
In a congenic Syrian hamster model in which all slow acetylators are homozygous for a single slow NAT2 allele or haplotype and obligate heterozygotes all possess the same combination of rapid and slow NAT2 allele or haplotype, the NAT2 acetylation polymorphism clearly segregates the N-acetylation of aromatic amine urinary bladder carcinogens such as ABP and BNA into three phenotypes in hepatic and extrahepatic tissues (Figure 1 ). This trimodal distribution of rapid, intermediate and slow acetylator phenotypes in Syrian hamsters congenic at NAT2 also is clearly evident in vivo (Figure 2) . Although many human studies often exhibit bimodal distributions of rapid and slow acetylator NAT2 phenotypes, studies with hydrazine drugs such as isoniazid (Parkin et al., 1997; Smith et al., 1997) , aromatic amine drugs such as sulfamethazine (Chapron et al., 1980; Lee and Lee, 1982) and caffeine, a compound with a metabolite that is N-acetylated Gross et al., 1999; Grant et al., 2004) , yield rapid, intermediate and slow acetylator phenotypes. The unequivocal detection of three phenotypes can be confounded by various factors including catalysis by NAT1. As isoniazid has high selectivity for catalysis via NAT2, rapid, intermediate and slow acetylator phenotypes can be readily and unequivocally discerned as illustrated in Figure 3 .
A widely held hypothesis is that human NAT2 is expressed primarily in the liver and gastrointestinal Hamster Urinary N-acetyl-PABA/PABA ratio Figure 2 Each bar represents mean7s.e. for urinary excretion ratio of N-acetyl-p-aminobenzoic acid to p-aminobenzoic acid in Syrian hamsters with homozygous rapid acetylator genotype (black), heterozygous acetylator genotype (gray) or homozygous slow acetylator genotype (white). Differences among the genotypes were highly significant (Po0.0001) following one-way analysis of variance. Adapted from Hein et al. (1994a) .
NAT2 polymorphism and urinary bladder cancer risk DW Hein tract, whereas human NAT1 has widespread tissue distribution. This hypothesis derives from studies in the rabbit model where N-acetyltransferase activities reflected the NAT2 genetic polymorphism in the liver and gut, but not in other tissue cytosols, suggesting either absence or a much smaller contribution of rabbit NAT2 in these other tissues (Hearse and Weber, 1973) . Furthermore, a subsequent study reported that the rapid/slow NAT2 ratio for both sulfamethazine Nacetyltransferase and N-hydroxy-ABP O-acetyltransferase activities were much higher in rabbit liver than small and large intestine (Ilett et al., 1991) . Thus, these studies in rabbit suggested that NAT2 genotype-dependent differences are expressed primarily in the liver and to a lesser extent in the gastrointestinal tract, and therefore suggest that NAT2 genotype-dependent differences in carcinogenesis following exposures to carcinogens primarily reflect NAT2 genotype-dependent hepatic versus extrahepatic metabolism of the carcinogen and/or its metabolites. Studies had shown expression of both NAT1 and NAT2 in human colon (Kirlin et al., 1991; Turesky et al., 1991; Ilett et al., 1994) , intestine (Hickman et al., 1998) and widespread tissue distribution of human NAT1 and NAT2 mRNA (Windmill et al., 2000; Boukouvala and Sim, 2005) . Although extrahepatic expression of N-acetyltransferase activities have been reported in humans (Pacifici et al., 1986) , rat (Hein et al., 1991a) , mouse (Chung et al., 1993; Stanley et al., 1997; Sugamori et al., 2003) and Syrian hamster (Hein et al., 1991b (Hein et al., , 1994a ) models, substrates were not selective for NAT1 and NAT2. NAT2-dependent ABP-and BNA N-acetyltransferase activities have been reported in human urinary bladder Frederickson et al., 1992 Frederickson et al., , 1994 Pink et al., 1992; Badawi et al., 1995) . p-Aminobenzoic acid N-acetyltransferase (selective for NAT1) and N-hydroxy-ABP O-acetyltransferase activities (not selective for NAT1 or NAT2) in human urinary bladder cytosols did not correlate, consistent with catalysis by both NAT1 and NAT2 (Badawi et al., 1995) . Other studies are consistent with N-acetylation of ABP and O-acetylation of N-hydroxy-ABP predominantly by NAT1 in urinary bladder (Frederickson et al., 1994) . Recent studies with substrates selective for NAT1 versus NAT2 reported widespread distribution of both NAT1 and NAT2 catalytic activities in the rapid and slow acetylator congenic hamster (Hein et al., in press ). NAT2-dependent N-acetylation ( Figure 1 ) and O-acetylation ( Figure 4 ) have been reported in urinary bladder cytosol from rapid and slow acetylator Syrian hamsters congenic at the NAT2 locus. As both NAT1 and NAT2 catalyse the metabolism of aromatic amine carcinogens (Minchin et al., 1992; Hein et al., 1993b Hein et al., , 1994b Hein et al., , 1995 , genetic polymorphism in NAT1 and/or NAT2 may modify cancer risk related to exposures to these carcinogens.
Molecular genetics
NAT1 and NAT2 are products of single, intronless exons containing single 870 bp open-reading frames encoding 290 amino acids (Blum et al., 1991; Vatsis et al., 1991) . NAT1, NAT2 and a pseudogene NATP are located on the short arm of human chromosome 8 NAT2 polymorphism and urinary bladder cancer risk DW Hein (Blum et al., 1990; Hickman et al., 1994) in the orientation NAT1:NATP:NAT2 (Matas et al., 1997) . NAT1 and NAT2 share 87% nucleotide homology in the coding region, yielding 55 aminoacid differences. Human NAT2 transcripts have been identified in many human tissues and derive from the protein-coding exon and a second non-coding exon of 100 bp located about 8 kb upstream of the translation start site (Blum et al., 1990; Ebisawa and Deguchi, 1991; Boukouvala and Sim, 2005) . A number of SNPs have been reported in the NAT2 coding exon. Those that cause amino-acid changes include 111T>C (R197Q), 190C>T (R64W), 191G>A (R64Q), 341T>C (I114T), 364G>A (D122N), 411A>T (L137F), 434A>C (Q145P), 590G>A (R197Q), 803A>G (K268R), 845A>C (K282T), 857G>A (K268R) and 859T>C (I287T). SNPs that do not change amino acids include 282C>T, 481C>T and 759C>T. 859T deletion also has been reported resulting in a frame shift at amino acid 287. Various combinations of SNPs are identified as NAT2 alleles (Vatsis et al., 1995) or haplotypes. NAT2*4 is considered the 'wild-type' allele or haplotype because of the absence of any SNPs. Variant NAT2 alleles or haplotypes possessing combinations of SNPs are segregated into clusters possessing a signature SNP either alone or in combination with others. The more common NAT2 alleles or haplotypes are illustrated in Table 1 . The frequency of NAT2 alleles varies widely across various ethnic groups and NAT2*4 is not the most common in most ethnic groups, including Caucasians and Africans (Figures 5 and 6 ). NAT2 alleles containing the 191G>A (R64Q), 341T>C (I114T), 590G>A (R197Q), or 857G>A (K268R) SNPs are associated with slow acetylator NAT2 alleles (Table 1) . Striking ethnic differences in the frequencies of SNPs and genotypes (http://snp500cancer.nci.nih.gov) are responsible for the corresponding ethnic differences in the frequency of rapid ( Figure 5 ) and slow ( Figure 6 ) acetylator NAT2 alleles or haplotypes and therefore Figure 5 Rapid acetylator NAT2 allelic (haplotype) frequencies reported in various populations. Data for each population was derived from the following sources: Germany , Spain (Agundez et al., 1996) , United Kingdom (UK), (Loktionov et al., 2002) , Poland (Lan et al., 2003) , Holland (van der Hel et al., 2003) , USA Caucasian (Deitz et al., 2000) , Nigeria (unpublished data from author's laboratory), South Africa (Loktionov et al., 2002) , Africa (Delomenie et al., 1996) , USA Black (O'Neill et al., 2000) , South India (Anitha and Banerjee, 2003) and Korea (Lee et al., 2002) .
NAT2 polymorphism and urinary bladder cancer risk DW Hein phenotypes. For example, the 191G>A (R64Q) SNP common to the NAT2*14 allele cluster is frequent in Africans and African-Americans, but virtually absent in Caucasian, Indian and Korean populations ( Figure 6) . Similarly, the NAT2*7 cluster possessing the 857G>A (K268R) SNP is much more frequent in South India and Korea than other populations, whereas the NAT2*5 cluster containing the 341T>C (I114T) SNP is much less frequent in Korea than in Europe, North America, India and Africa ( Figure 6 ). Deduction of NAT2 phenotypes is assigned based on co-dominant expression of rapid and slow acetylator NAT2 alleles or haplotypes as clearly documented in animals (Figures 1 and 2 ) and humans ( Figure 3 ). Individuals homozygous for rapid NAT2 acetylator alleles are deduced as rapid acetylators, individuals homozygous for slow acetylator NAT2 alleles are deduced as slow acetylators and individuals possessing one rapid and one slow NAT2 allele are deduced as intermediate acetylators.
Over 35 NAT2 alleles or haplotypes have been identified in human populations. A consensus NAT nomenclature was first published in 1995 (Vatsis et al., 1995) . An international nomenclature committee publishes an Internet-accessible website for allele updates at www.louisville.edu/medschool/pharmacology/ NAT.html.
Molecular basis for altered function of NAT2 polymorphic variants
Reductions in the amount of NAT2 protein expressed in human liver from individuals with slow acetylator phenotype have been reported (Deguchi et al., 1990; Grant et al., 1990; Deguchi, 1992) . Slow acetylator NAT2 alleles recombinantly expressed in COS-1 cells (Blum et al., 1991; Zang et al., 2004) , Chinese hamster ovary cells (Abe et al., 1993) and yeast (Leff et al., 1999; Fretland et al., 2001) show reduced levels of NAT2 protein when compared with NAT2*4. These data suggest that slow acetylator phenotype is conferred, at least for some NAT2 alleles, by reduction(s) in NAT2 protein. Recent studies in COS-1 cells also show that the reduction in protein in slow acetylators is the result of increased degradation for SNPs such as 341T>C (I114T) (Zang et al., 2004) .
The effects of NAT2 SNPs on catalytic activities have been investigated primarily in recombinant expression systems (reviewed in Hein et al., 2000; Hein, 2002) . Nucleotide substitutions identified in human NAT2 allelic variants yield reductions in substrate affinity, catalytic activity and/or protein stability of the recombinant N-acetyltransferase allozymes. Recombinant human NAT2 5, NAT2 6, NAT2 7 and NAT2 14 clusters yield variable reductions in catalytic activity associated with slow acetylator phenotype, whereas recombinant human NAT2 12 and NAT2 13 clusters catalyse N-, Oand N, O-acetyltransferase activities at levels comparable to the rapid acetylator NAT2 4 . Recently, some controversy has arisen regarding the assignment of NAT2*12 and NAT2*13 as rapid acetylator alleles (Bolt et al., 2005) . As shown in Table 1 , NAT2*12 allele clusters possess the signature 803A>G (K268R) SNP, whereas the NAT2*13 allele possesses the 282C>T SNP that does not change the amino acid. These two SNPs and identification of NAT2*12 and NAT2*13 alleles often are not determined in epidemiological studies as they are considered rare. However, as shown in Figure 5 , their frequency is not rare in many ethnic groups and it is important both to assess their frequency and to correctly assign them as rapid or slow (Hein et al., 1994b Fretland et al., 2001; Zang et al., 2005) . Three studies using caffeine as a phenotype probe suggested that NAT2*12 and NAT2*13 were associated with slow acetylation phenotype (Cascorbi et al., 1995; Gross et al., 1999; Bolt et al., 2005) . Cascorbi et al. (1995) initially reported this for NAT2*13, but later reported that it was related to an NAT2 genotyping artifact . The other studies did not distinguish the NAT2*12 or the NAT2*13 allele from NAT2 genotypes that do not possess NAT2*12 or NAT2*13. Nevertheless, verification of NAT2*12 and NAT2*13 as rapid acetylator alleles has been provided in vivo Parkin et al., 1997) . The latter study (Parkin et al., 1997) included five subjects possessing the NAT2*13 allele and 20 subjects possessing the NAT2*12A allele that consistently confirmed rapid acetylator status based upon measured phenotypes in several people. Recombinant NAT2 proteins differ in heat stability (Ferguson et al., 1994; Hein et al., 1994b; Grant et al., 1997; Leff et al., 1999; Fretland et al., 2001) . The NAT2 7B allozyme has altered affinity for some but not other substrates (Hein et al., 1994b; Hickman et al., 1995) , suggesting that the expression of acetylator phenotype is dependent upon the substrate. Some, but not all of the SNPs in human NAT2 yield reductions in quantity of recombinant NAT2 protein in eukaryotic expression systems (Blum et al., 1991; Deguchi, 1992; Abe et al., 1993; Leff et al., 1999; Fretland et al., 2001) . Clearly, more data from tissues is needed to investigate tissuespecific and other regulatory factors.
As multiple mechanisms for reductions in NAT2 activity are associated with various combinations of SNPs that make up NAT2 alleles, the ability to distinguish among multiple acetylator phenotypes is complex and a function of the sensitivity and specificity of the phenotyping method. Phenotype is influenced by a number of factors including diet, disease and drug therapy. Depending upon the probe drug and analytical method used, acetylation phenotypes often exhibit overlap owing to numerous genetic and/or environmental factors, including the large number and diversity of NAT2 genotypes present in human populations. The relative specificity of the substrate for NAT2 versus NAT1 at the concentrations obtained in vivo will also affect acetylator phenotype. Caffeine is commonly used as a probe drug for NAT2 phenotype determinations because it is relatively non-invasive and excellent NAT2 genotype/phenotype correlations have been reported (Cascorbi et al., 1995; Grant et al., 1997 Grant et al., , 2004 ). Genetic and/or environmental effects on a number of enzyme systems (e.g., cytochrome P450, xanthine oxidase, NAT1) may affect metabolite levels used to assess phenotype. Other potential artifacts in the use of caffeine to determine acetylation phenotype also have been reported (Lorenzo and Reidenberg, 1989; Cribb et al., 1994; O'Neil et al., 2000; Svensson and Hein, 2004) .
NAT2 polymorphism and urinary bladder cancer risk
Human epidemiological studies have investigated the role of the NAT2 polymorphism in many cancers. Urinary bladder is a textbook example as individuals are frequently exposed to aromatic amine urinary bladder carcinogens such as ABP and BNA in cigarette smoke (Luceri et al., 1993; Stabbert et al., 2003) . These aromatic amine carcinogens require metabolic activation in order to mutate DNA and initiate carcinogenesis. Following N-oxidation, the N-hydroxy-aromatic and Nhydroxy-heterocyclic amines are further activated (via O-acetylation) by N-acetyltransferases to acetoxy intermediates, which react spontaneously with DNA to form DNA adducts (Hein, 1988) . Thus, biological plausability for relationships between the NAT2 acetylation polymorphisms are strongest for cancers related to aromatic amine exposures.
The role of rapid versus slow acetylator genotype in cancer predisposition differs between organ sites as might be expected with tissue-specific expression of NAT2. Although reports of associations between NAT2 polymorphism and a number of cancers have been reported, a focus on urinary bladder cancer is useful for illustrating the divergent effects of carcinogenic agent and NAT2 haplotype on individual risk.
The first association between slow acetylator phenotype and urinary bladder cancer was reported over 25 years ago (Lower et al., 1979) . The hypothetical mechanism for this association is slow NAT2 acetylation of aromatic amine carcinogens competes poorly with metabolic activation via cytochrome P450(s) and/ or prostaglandin H-synthases, thus accounting for higher risk in the slow NAT2 phenotype(s). In a landmark study, English chemical dye workers with documented exposure to aromatic amine carcinogens showed a striking association (OR ¼ 16.7; P ¼ 0.00005) between urinary bladder cancer and slow acetylator phenotypes (Cartwright et al., 1982) . The population studied had documented exposures to aromatic amines and NAT2 acetylator phenotype was assessed by measurement of plasma monoacetyl-dapsone to dapsone metabolic ratios. Dapsone is an NAT2-selective substrate (more so than caffeine) and measurement of monoacetyl-dapsone to dapsone metabolic ratios in plasma (rather than urine) is a more direct assessment of NAT2 phenotype. Interestingly, the NAT2 phenotype data was not separated into two phenotypes (rapid and slow), but rather into eight ranges of metabolic ratios. Five of these ratios (0.3 and greater) correspond to rapid acetylators, and the other three (0.01-0.09, 0.1-0.19 and 0.2-0.29) correspond to different levels of slow acetylator phenotype. As reviewed previously (Hein, 2002) , urinary bladder cancer risk increased as NAT2 metabolic ratio (phenotype) decreased (P trend ¼ 0.0006). The risk was markedly increased in the slowest NAT2 phenotype (OR, 20.8; 95% CI, . Four studies found that urinary bladder cancer risk was highest in individuals possessing NAT2*5 haplotypes Okkels et al., 1997; Filiadis et al., 1999; El Desoky et al., 2005) . The 341T>C (I114T) SNP associated with NAT2*5 alleles or haplotypes yields very large reductions in NAT2 protein and activity (Hein et al., 1994b Fretland et al., 2001) , resulting from protein degradation (Zang et al., 2004) . Recently, NAT2*5 alleles also were associated with increased risk for breast cancer in women smokers (van der Hel et al., 2003) . These results suggest that NAT2 slow acetylator phenotype is not homogeneous, but rather that multiple slow acetylator phenotypes exist resulting from different mechanisms inferred by various SNPs and haplotypes.
Among smokers, NAT2 slow acetylators have higher levels of 4-ABP hemoglobin adducts (Vineis et al., 1994; Yu et al., 1994; Probst-Hensch et al., 2000) . Furthermore, ABP-DNA adducts in higher grade bladder tumors are found at higher levels in smokers who are slow NAT2 acetylators (Airoldi et al., 2002; Hao et al., 2004) . A previous review of 21 published case-control studies reported that experimental evidence was not sufficient to conclude a real increase in risk for urinary bladder cancer in slow NAT2 acetylators (Green et al., 2000) . However, subsequent studies carried out in Europe (Vineis et al., 2001) , Japan (Tsukino et al., 2004) , the United States (Gu et al., 2005) and Spain (Garcia-Closas et al., 2005) each reported that NAT2 slow acetylators had a significantly increased risk of urinary bladder cancer that was stronger in smokers, (Woodhouse et al., 1982; Miller and Cosgriff, 1983; Hanssen et al., 1985; Ladero et al., 1985; Mommsen and Wolf, 1985; Karakaya et al., 1986; Kaisary et al., 1987; Horai et al., 1989; Dewan et al., 1995; Ishizu et al., 1995; Risch et al., 1995; Peluso et al., 1998; Su et al., 1998; Taylor et al., 1998; Hsieh et (Tsukino et al., 2004) . Meta-analysis of these and all previous studies show that the overall association with slow NAT2 genotype in the published literature is robust (Figure 7) providing compelling evidence for a role of NAT2 acetylator genotype in urinary bladder cancer associated with aromatic amines in cigarette smoke. As ethnic differences in NAT2 allele frequencies are quite striking (Figures 5 and 6) , it has been suggested that that the role of NAT2 polymorphism on urinary cancer risk may differ with ethnic group (Golka et al., 2002) . However, strong evidence has been provided by Carreon et al. (2006) that this is not the case, but rather that the role of NAT2 polymorphism on urinary bladder cancer risk differs with carcinogenic agent. Although one study found no difference in urinary bladder cancer risk between rapid and slow NAT2 acetylator Chinese workers , another study of Chinese workers exposed to benzidine , subsequently confirmed in a follow-up study (Carreon et al., 2006) , reported that slow NAT2 acetylator genotype was associated with decreased risk to urinary bladder (relative to rapid NAT2 acetylators). As noted above and in Figure 7 , the effect of NAT2 polymorphism on urinary bladder cancer risk for smokers is not dependent upon ethnic group. Rather than an ethnic difference, these findings are explained by the observation that as benzidine is a diarylamine, the N-acetylation of one aromatic amine moiety is not a deactivation step and may enhance metabolic activation and/or transport to the urinary bladder. Urinary bladder DNA adducts following benzidine exposures in humans derive from Nacetylated metabolite(s) (Rothman et al., 1996) . Support for this hypothesis also derives from the effect of NAT2 polymorphism on hepatoxicity from the diarylamine 4,4 0 -methylenedianiline in the rat (Zhang et al., 2006) . NAT2 rapid acetylators potentially would be at decreased risk of urinary bladder cancer following dermal exposures to aromatic amine carcinogens if NAT2 were highly expressed in skin, as a rapid NAT2 acetylator phenotype would have higher capacity to deactivate the carcinogen before systemic absorption. The lack of NAT2 expression in human kerotinocytes (Reilly et al., 2000) is consistent with increased risk of urinary bladder cancer in NAT2 slow acetylators following dermal exposures (Gago-Dominguez et al., 2003) . Thus, following both inhalation and dermal exposures to aromatic monoarylamines, N-acetylation competes with N-hydroxylation conferring higher risk to the slow NAT2 acetylator phenotype(s). Furthermore, local N-or Oacetylation of arylamines or their N-hydroxylated metabolites resulting from dermal exposures would not be modified by NAT2 acetylation polymorphism, except indirectly to the extent that there is linkage disequilibrium between NAT1 and NAT2 alleles.
The effect of NAT2 acetylator polymorphism on urinary bladder cancer susceptibility is dependent upon accuracy of the exposure and genotype assessments Deitz et al., 2004) . Indeed, reports suggest that ABP is present in higher yields in sidestream versus mainstream cigarette smoke and aromatic amines are present in indoor environments exposed to side stream cigarette smoke (Luceri et al., 1993; Palmiotto et al., 2001) . As exposure to passive smoking may also increase urinary bladder cancer risk, studies that use controls not exposed to passive cigarette smoke may yield more robust findings. NAT2 genotyping methods resulting in misclassification may confound relationships between NAT2 acetylator polymorphism and urinary bladder cancer risk (Deitz et al., 2004) . Functional understanding of the effects of NAT2 genetic polymorphisms on metabolism and genotoxicity, tissuespecific expression and the molecular mechanisms responsible for these effects are critical for the interpretation of previous and future human molecular epidemiology studies.
